# Safety and Tolerability Study of 2 Dose Level of Arikayce™ in Patients With Bronchiectasis and Chronic Infection Due to Pseudomonas Aeruginosa.

> **NCT00775138** · PHASE2 · COMPLETED · sponsor: **Insmed Incorporated** · enrollment: 64 (actual)

## Conditions studied

- Bronchiectasis

## Interventions

- **DRUG:** 280 mg Arikayce™
- **DRUG:** Matching Placebo for Cohort 1
- **DRUG:** 560 mg Arikayce™
- **DRUG:** Matching Placebo for Cohort 2

## Key facts

- **NCT ID:** NCT00775138
- **Lead sponsor:** Insmed Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-06-24
- **Primary completion:** 2009-05-11
- **Final completion:** 2009-05-11
- **Target enrollment:** 64 (ACTUAL)
- **Last updated:** 2019-07-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00775138

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00775138, "Safety and Tolerability Study of 2 Dose Level of Arikayce™ in Patients With Bronchiectasis and Chronic Infection Due to Pseudomonas Aeruginosa.". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00775138. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*